Financials Revolution Medicines, Inc.

Equities

RVMD

US76155X1000

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 09/02/2026 GMT			5-day change	1st Jan Change
96.74 ^USD	-0.77%		-0.22%	+21.46%

01-29	Revolution Medicines Says First Patient Dosed in Solid Tumor Trial	MT
01-29	Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective Inhibitor	CI

Projected Income Statement: Revolution Medicines, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
Net sales ¹	42.98	29.39	35.38	11.58	-	3.678	33.65	306.4
Change	-	-31.62%	20.38%	-67.27%	-	-	815.08%	810.49%
EBITDA ¹	-108.1	-184.9	-253.2	-481.1	-681.9	-1,126	-1,343	-1,251
Change	-	-71.09%	-36.94%	-89.97%	-41.74%	-65.08%	-19.3%	6.86%
EBIT ¹	-110.7	-188	-258.3	-487.2	-689.5	-1,140	-1,346	-1,257
Change	-	-69.84%	-37.38%	-88.63%	-41.53%	-65.29%	-18.05%	6.56%
Interest Paid ¹	-0.071	-	-	-	-2.528	-16.06	-22.59	-49.18
Earnings before Tax (EBT) ¹	-108.5	-187.1	-249.1	-439.9	-600.8	-1,068	-1,301	-1,179
Change	-	-72.39%	-33.16%	-76.57%	-36.59%	-77.68%	-21.84%	9.39%
Net income ¹	-110.4	-187.1	-248.7	-436.4	-600.1	-1,064	-1,287	-1,151
Change	-	-69.5%	-32.93%	-75.46%	-37.52%	-77.36%	-20.91%	10.58%
Announcement Date	02/03/21	28/02/22	27/02/23	26/02/24	26/02/25	-	-	-

¹USD in Million

Estimates

Fiscal Period: December	2020 Q4	2021 Q1	2021 Q2	2021 Q3	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2026 Q1	2026 Q2	2026 Q3	2026 Q4	2027 Q1	2027 Q2	2027 Q3
Net sales ¹	8.751	10.13	8.698	1.101	9.46	7.578	9.116	3.356	15.33	7.014	3.824	-	0.742	-	-	-	-	-	-	-	3.678	2.967	2.967	2.967	16.67	30	50	70
Change	-	15.77%	-14.14%	-87.34%	759.22%	-19.89%	20.3%	-63.19%	356.79%	-54.25%	-45.48%	-	-	-	-	-	-	-	-	-	-	-19.34%	0%	0%	462.06%	79.91%	66.67%	40%
EBITDA ¹	-	-	-	-	-	-	-	-	-	-	-	-	-178.4	-139.1	-154.7	-174.1	-214.3	-238.8	-262.7	-312.9	-314.4	-341.1	-358.4	-371.1	-342.4	-311.2	-295.4	-282.9
Change	-	-	-	-	-	-	-	-	-	-	-	-	-	22.04%	-11.28%	-12.5%	-23.12%	-11.43%	-10%	-19.13%	-0.48%	-8.48%	-5.07%	-3.54%	7.75%	9.1%	5.08%	4.22%
EBIT ¹	-34.08	-37.4	-44.54	-53.16	-52.91	-57.95	-62.09	-76.53	-61.71	-75.16	-108.8	-123.2	-180	-140.9	-156.6	-175.7	-216.3	-240.8	-264.7	-315.3	-320.4	-328.5	-339.6	-348.4	-344.8	-312.4	-296.7	-281
Change	-	-9.73%	-19.09%	-19.37%	0.47%	-9.52%	-7.14%	-23.26%	19.37%	-21.8%	-44.76%	-13.28%	-46.03%	21.74%	-11.21%	-12.17%	-23.1%	-11.3%	-9.95%	-19.1%	-1.62%	-2.54%	-3.38%	-2.6%	1.03%	9.4%	5.04%	5.28%
Charge d'intérêts ¹	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-11.43	-7.164	-2.9	-5.6	-5.6	-5.6	-	-	-
Earnings before Tax (EBT) ¹	-33.84	-37.18	-44.3	-52.94	-52.68	-57.65	-61.22	-73.63	-56.63	-68.1	-98.3	-112.3	-161.2	-116	-133.2	-156.3	-195.3	-213.4	-247.8	-305.2	-307.4	-313.5	-324.6	-333.9	-330.8	-301	-287.9	-274.8
Change	-	-9.85%	-19.16%	-19.51%	0.5%	-9.44%	-6.2%	-20.26%	23.08%	-20.25%	-44.35%	-14.25%	-43.54%	28.04%	-14.85%	-17.3%	-24.98%	-9.26%	-16.11%	-23.17%	-0.71%	-1.98%	-3.54%	-2.89%	0.94%	9.01%	4.34%	4.56%
Net income ¹	-34.2	-37.18	-44.3	-52.94	-52.68	-57.65	-61.22	-73.33	-56.51	-68.1	-98.3	-108.4	-161.5	-116	-133.2	-156.3	-194.6	-213.4	-247.8	-305.2	-300.5	-311.2	-321.5	-330.7	-323.9	-301	-287.9	-274.8
Change	-	-8.69%	-19.16%	-19.51%	0.5%	-9.44%	-6.2%	-19.78%	22.94%	-20.51%	-44.35%	-10.31%	-48.97%	28.19%	-14.85%	-17.3%	-24.49%	-9.69%	-16.11%	-23.17%	1.53%	-3.53%	-3.34%	-2.83%	2.04%	7.08%	4.34%	4.56%
Announcement Date	02/03/21	10/05/21	11/08/21	10/11/21	28/02/22	09/05/22	09/08/22	07/11/22	27/02/23	08/05/23	08/08/23	06/11/23	26/02/24	08/05/24	07/08/24	06/11/24	26/02/25	07/05/25	06/08/25	05/11/25	-	-	-	-	-	-	-	-

¹USD in Million

Estimates

Forecast Balance Sheet: Revolution Medicines, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
Net Debt ¹	-	-577	-645	-1,853	-2,289	-519	-	-364
Change	-	-	-11.79%	-187.29%	-23.53%	77.33%	-	-
Announcement Date	02/03/21	28/02/22	27/02/23	26/02/24	26/02/25	-	-	-

¹USD in Million

Estimates

Cash Flow Forecast: Revolution Medicines, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
CAPEX ¹	2.933	6.528	10.82	7.729	10.31	13.42	9.903	9.903
Change	-	122.57%	65.69%	-28.54%	33.37%	30.23%	-26.23%	0%
Free Cash Flow (FCF) ¹	-103	-153.7	-235.2	-358.3	-567.7	-978.8	-1,224	-1,202
Change	-	-49.24%	-53.03%	-52.33%	-58.45%	-72.39%	-25.03%	1.78%
Announcement Date	02/03/21	28/02/22	27/02/23	26/02/24	26/02/25	-	-	-

¹USD in Million

Estimates

Forecast Financial Ratios: Revolution Medicines, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
Profitability
EBITDA Margin (%)	-251.46%	-629.21%	-715.77%	-4,154.36%	-	-30,607.36%	-3,990.25%	-408.17%
EBIT Margin (%)	-257.54%	-639.7%	-730.01%	-4,207.12%	-	-30,990%	-3,998.01%	-410.3%
EBT Margin (%)	-252.5%	-636.58%	-704.14%	-3,798.71%	-	-29,027.18%	-3,864.74%	-384.62%
Net margin (%)	-256.8%	-636.58%	-702.95%	-3,768.28%	-	-28,940.11%	-3,823.91%	-375.56%
FCF margin (%)	-239.62%	-522.99%	-664.83%	-3,094.14%	-	-26,612.52%	-3,636.22%	-392.25%
FCF / Net Income (%)	93.31%	82.16%	94.58%	82.11%	94.61%	91.96%	95.09%	104.44%
Profitability
ROA	-28.02%	-28.66%	-32.11%	-30.38%	-25.98%	-47.95%	-87.27%	-154.14%
ROE	-68.54%	-34.74%	-38.63%	-34.76%	-29.33%	-55.63%	-118.05%	-309.38%
Financial Health
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-
Debt / Free cash flow	-	-	-	-	-	-	-	-
Capital Intensity
CAPEX / Current Assets (%)	6.82%	22.21%	30.57%	66.74%	-	365%	29.43%	3.23%
CAPEX / EBITDA (%)	-2.71%	-3.53%	-4.27%	-1.61%	-1.51%	-1.19%	-0.74%	-0.79%
CAPEX / FCF (%)	-2.85%	-4.25%	-4.6%	-2.16%	-1.82%	-1.37%	-0.81%	-0.82%
Items per share
Cash flow per share ¹	-	-	-	-3.098	-3.323	-4.538	-5.134	-
Change	-	-	-	-	-7.26%	-36.55%	-13.14%	-
Dividend per Share ¹	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-
Book Value Per Share ¹	8.65	8.127	7.578	16.14	13.5	8.209	4.857	0.2492
Change	-	-6.05%	-6.75%	112.97%	-16.33%	-39.21%	-40.83%	-94.87%
EPS ¹	-2.01	-2.57	-3.08	-3.86	-3.58	-5.586	-6.532	-5.656
Change	-	-27.86%	-19.84%	-25.32%	7.25%	-56.04%	-16.92%	13.41%
Nbr of stocks (in thousands)	66,380	73,687	88,791	164,565	184,795	193,320	193,320	193,320
Announcement Date	02/03/21	28/02/22	27/02/23	26/02/24	26/02/25	-	-	-